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Recent reports have indicated that antipsychotic drugs exert their
clinical effects earlier than previously thought, with the largest
treatment effect occurring within 2-4 weeks, which has challenged
the concept of delayed onset of action of antipsychotics.1,2
However, none of these studies investigated time to response in
treatment-resistant schizophrenia. This is clinically important,
since it is known that such patients constitute about a third of
treated cases.3 Moreover, these individuals are often subjected to
multiple trials of antipsychotic drugs, including clozapine,
without clear guidance as to the trial duration that could be
considered adequate prior to moving to the subsequent strategies.
For instance, time to response remains a controversial issue even
with clozapine, a gold standard antipsychotic medication in
treatment-resistant schizophrenia.4,5 At least one shorter-term
investigation has demonstrated that a degree of improvement in
Brief Psychiatric Rating Scale (BPRS) scores at 1 week can predict
favourable outcome at 5 weeks.6 Further, some longer-term
studies are not supportive of treatment response beyond 6–8
weeks.7,8 Nevertheless, another report showed that 55% of
treatment response occurred after 6 weeks in individuals treated
for a mean of 10 months (s.d. = 8).9 In addition, Meltzer et al
reported that 20 of 36 participants classified as responders
(response defined as more than 20% decrease in BPRS score) were
identified after 6 weeks of treatment with clozapine.10 A majority
of treatment response (70%; n= 14) was also attained later than 6
weeks if a threshold of response was set more stringently (i.e. a
50% or more decrease in BPRS score). Moreover, Zito et al
reported that although 19% of patients exhibited improvement
at 6 weeks, the response rate increased to 29% at 12 weeks.11
Indeed, one guideline recommends treatment to be continued
for at least 8 weeks.12 However, clinicians have no guidance on
when to consider a clozapine trial as failed, a question of major
clinical relevance considering the adverse effects profile of this
medication. We therefore conducted a systematic review of the
literature in treatment-resistant schizophrenia to address response
rates and time-line to response, focusing specifically on early
improvement in this population.
Method
A literature search was conducted systematically to identify
randomised, double-blind clinical trials of antipsychotics in adult
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Background
Improvements are greatest in the earlier weeks of
antipsychotic treatment of patients with non-resistant
schizophrenia.
Aims
To address the early time-line for improvement with
antipsychotics in treatment-resistant schizophrenia.
Method
Randomised double-blind trials of antipsychotic medication in
adult patients with treatment-resistant schizophrenia were
investigated (last search June 2010). A series of meta-
regression analyses were carried out to examine the effect
of time on the average item scores in the Positive and
Negative Syndrome Scale (PANSS) or Brief Psychiatric Rating
Scale (BPRS) at three or more distinct time points within the
first 6 weeks of treatment.
Results
Study duration varied from 4 weeks to 1 year and the
definitions of treatment resistance as well as of treatment
response were not necessarily consistent across 19 identified
studies, resulting in highly variable rates of response (0–76%).
The mean standardised baseline item score in the PANSS
or BPRS was 3.4 (s.e. = 0.06) in the five studies included
in the meta-regression analysis, with the average baseline
Clinical Global Impression – Severity score being 5.2 (marked
illness). For the pooled population treated with a range of
antipsychotics (n=1019), significant reductions in the mean
item scores occurred during the first 4 weeks; improvements
observed in later weeks were smaller and non-significant. In
contrast, weekly improvement with clozapine was significant
throughout (n=356).
Conclusions
Our findings provide preliminary evidence that the majority of
improvement with antipsychotics may occur relatively early.
More consistent improvements with clozapine may be
associated with a gradual titration. To further elucidate
response patterns, future studies are needed to provide data
over regular intervals during earlier stages of treatment.
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patients with treatment-resistant schizophrenia. PubMed, Ovid
Medline (since 1950), EMBASE (since 1980) and PsycINFO (since
1967) through June 2010 were searched with key words ‘treatment
resistant schizophrenia’ AND ‘double blind’. A search was also
conducted by replacing ‘treatment resistant schizophrenia’ with
‘refractory schizophrenia’. Studies with fewer than ten adult
patients in the treatment arms, studies for which response rate
was not reported and dose-finding studies were excluded.
Likewise, augmentation studies after run-in antipsychotic
treatment were excluded.
Qualitative analysis
Each study was examined in terms of definition of treatment
resistance. Definition of treatment response, rate of response,
premature attrition rate and data reporting points were also
investigated, to give an indication of time to antipsychotic
response in treatment-resistant schizophrenia.
Statistical analysis
To investigate potentially early treatment improvement or onset of
action, publications that reported at least three last observation
carried forward (LOCF) data points in the Positive and Negative
Syndrome Scale (PANSS; each item scored 1–7) or BPRS (each
item scored 1–7) up to the first 6 weeks of treatment were
extracted and mean item scores calculated by dividing the total
score by 30 or 18 respectively. This method is in accordance with
a previous investigation of early response to antipsychotics in
non-resistant schizophrenia,2 and allows for the relative scarcity
of available data points (see Results). The LOCF scores during
the first 6 weeks of treatment were either reported as absolute
scores in the original article (1 study),13 obtained by the authors
on request (1 study),14 or determined from the accompanying
figures detailing change over this period (3 studies)5,15,16 in the
studies included in our meta-regression analyses. Data solely
concerning clozapine were considered separately. Also, data on
second-generation antipsychotics (other than clozapine) and
study completer groups were investigated for descriptive purposes
only.
A series of meta-regressions were carried out (via weighted
mixed models analyses) using SAS version 9.1.3. for Windows
to establish the time course of treatment response among
participants with treatment-resistant schizophrenia. These models
make less restrictive assumptions than many standard statistical
tests (i.e. we need not to assume that our residuals are
independent when using mixed models) and are appropriate for
use when studying longitudinal data. Full maximum likelihood
estimation was selected as the method of estimation for each of
these analyses, and a variety of potential residual covariance
structures (variance components, first-order autoregressive,
compound symmetric, heterogeneous first-order autoregressive,
heterogeneous compound symmetric, and unstructured) were
investigated in each model. Although the structure and
interpretation of the residual covariance matrix are of little clinical
interest and do not relate directly to our research questions, we
chose to investigate this series of modelling assumptions in order
to identify the models and series of assumptions that best fit our
data. This in turn improved the precision of our estimates (i.e.
reduced the magnitude of standard errors in the estimates), which
affects hypothesis testing related to our research questions.
To determine objectively which of these structures most
accurately represents the true residual covariance structure within
each of our investigations, we chose to examine the Bayesian
information criteria (BIC) associated with each model – a
goodness-of-fit statistic that penalises the model’s likelihood
function based on both model complexity (the number of
parameters requiring estimation) and sample size. Use of this
statistic allows us to identify the most parsimonious model (the
model requiring estimation of the fewest parameters) which best
fits our sample data. A smaller BIC indicates a better fit when
comparing models, and the covariance structure ultimately
adopted was the one that yielded the smallest BIC value for each
of our analyses.
As one cannot reasonably assume independence of results
across study arms within the same study, the findings for each
of the two drug treatment groups within a given study were
pooled to reflect a single set of results for each study, using a
weighted average of the standardised scores across the two drug
groups at each time point. Baseline sample sizes (pooled across
treatment arms) for each study were used as sample weights in
all analyses.
Percentage reduction in PANSS scores was obtained by taking
into account the non-deductible value of the scale (i.e. 30);17 for
instance, if the baseline mean item score was 4.0 (120 in total),
a 20% reduction was defined as a post-treatment mean item score
of 3.4, i.e. a total score of 102; note that (1027120)/(120730)
equals 70.2.
Results
The literature search using the key words ‘treatment resistant
schizophrenia’ and ‘double blind’ located 14 studies and a
replacement of the former search term with ‘refractory
schizophrenia’ found five studies (Fig. 1). In total, 19 manuscripts
reporting response rates following antipsychotic treatment of
treatment-resistant/refractory schizophrenia in adult patients
were identified (online Tables DS1 and DS2).5,13,14–16,18–31 The
definition of treatment resistance varied among studies, although
it invariably included past failure to respond to one or more anti-
psychotics at chlorpromazine equivalent doses of 400–1000mg.
Similarly, the definitions of treatment response were not
necessarily consistent, although they universally adopted a
specified degree of improvement in the representative rating scales
(typically a 20–30% decrease in PANSS or BPRS score).
Study duration varied from 4 weeks to 1 year, with the
majority (63%) lasting for 12 weeks or less (12 of 19 studies).
In the light of these differences it is not surprising to note that
both response rates and premature attrition rates were variable
(0–76% and 2–72% respectively). A total of 11 antipsychotics were
included in these studies, with the most frequently studied being
clozapine (ten studies), haloperidol (seven), chlorpromazine
(five), olanzapine (five) and risperidone (four). Only nine reports
(47%) described data on key outcomes throughout available
points; for the remainder, data were either unclear regarding
assessment points, were selectively reported or were not fully
provided throughout the treatment period (e.g. pre- and post-
treatment presentation only). Only one study explicitly reported
the rate of response through week 6 (excepting week 5).15 Results
of this study showed a continuous increase in the percentage of
responders (observed cases) for aripiprazole, whereas the slope
of increase was more gradual for perphenazine after 3 weeks. In
contrast, LOCF data from an intent-to-treat (ITT) sample implied
the largest decrease in average PANSS scores in the first 3–4 weeks.
Meta-regression analysis
Studies included
One complex study that adopted a multiple transition among
antipsychotics was excluded from the meta-regression analysis.20
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Thirteen additional studies were excluded on the basis of having
two or fewer data reporting points within 6 weeks (Table DS1).
A total of five studies that reported on the rating scale scores
through week 6 were included for meta-regression (Table
DS2).5,13,14–16 Each study had two treatment arms and the anti-
psychotics studied were clozapine (four studies), olanzapine
(two), aripiprazole, chlorpromazine, perphenazine and ziprasidone
(one study each). Clozapine treatment was gradually increased
over several weeks to the target doses, ranging from 100mg to
900mg. The study samples were predominantly male (60–80%,
where indicated) with an average age of 36–42 years. As expected,
the average score on the Clinical Global Impression – Severity
(CGI-S) scale was relatively high at 5.2, corresponding to marked
illness. Except in one study,5 patients with drug resistance and
those with intolerance were both recruited; however, the results
of these studies were not stratified by resistance or intolerance.
With the exception of one study that described continuous data
on BPRS four key items and an anergia item,5 positive v. negative
symptoms data were either presented as pre- and post-treatment
data,13,14,16 or not presented separately.15 Affective or cognitive
symptoms were not addressed in these studies. All studies adopted
a flexible dosing design, and the PANSS was used by all studies
except for one that used the BPRS.5
Analysis
Considering all antipsychotics, a first-order autoregressive
covariance structure was found to yield the best fit among the
various structures tested (five studies, n= 1019). Standardised
mean item scores were found to change significantly over the
course of the 6-week period (F=34.68, d.f. = 6,22, P50.0001).
Bonferroni-adjusted pairwise comparisons found that the baseline
scores were significantly higher than the scores observed at all
other time points (adjusted P50.0001). Week 1 standardised
mean item scores were significantly higher than those observed
at all subsequent time points (P50.0001 in each case). Week 2
scores were also significantly higher than those observed at weeks
3–6 (P50.0001). Week 3 scores were significantly higher than
scores at weeks 4–6 (P=0.00268, 0.0086 and 0.0004 respectively).
Week 4 scores were significantly higher than scores at week 6
(P=0.0172) but did not differ from week 5 scores (P=0.6909).
Scores at weeks 5 and 6 were not significantly different from each
other (P=0.7679). The mean standardised scores at each time
point are summarised in Fig. 2.
For clozapine, a heterogeneous first-order autoregressive
covariance structure was found to yield the best fit among the
various structures tested (four studies, n= 356). Standardised
mean item scores were found to change significantly over the
course of the study (F=90.91, d.f. = 6,18, P50.0001).
Bonferroni-adjusted pairwise comparisons found that the baseline
scores were significantly higher than the scores observed at all
other time points (baseline v. week 1 P= 0.0177; baseline v. weeks
2–6 P50.0001). Week 1 scores were significantly higher than
those observed at all subsequent time points (P50.0001 in each
case). Week 2 scores were also significantly higher than those
observed at weeks 3–6 (P50.0001). Week 3 scores were
significantly higher than scores at weeks 4–6 (P=0.0007,
50.0001 and 50.0001 respectively). Week 4 scores were
significantly higher than scores at weeks 5 and 6 (P= 0.0002 and
50.0001 respectively). Week 5 scores were also significantly
higher than week 6 scores (P= 0.0003). The mean standardised
scores at each time point are summarised in Fig. 3.
The mean standardised item scores were 3.4 for all antipsycho-
tics and 3.5 for clozapine, corresponding to a PANSS score of 103.
This baseline score was higher than that previously reported for
patients with non-resistant schizophrenia by about 10 points.2
Overall, a 20% decrease was noted at week 4, and a 30% decrease
was not achieved by the end of week 6 for all antipsychotics
pooled. In contrast, for clozapine alone a 20% decrease was noted
at week 3 and this increased further to 30% by week 6. An
improvement of 0.17 for all antipsychotics (29% of the improve-
ment from baseline through week 6) and 0.27 for clozapine (33%)
was noted in weeks 4–6. Thus, approximately two-thirds of the
improvement observed in 6 weeks occurred within the first 3
weeks. Nevertheless, a smaller improvement over the following
3 weeks corresponded to a further 5.1 point decrease in PANSS
scores for all antipsychotics and 8.1 points for clozapine.
The results for second-generation antipsychotics other than
clozapine (four studies, n=380) and for completer-only samples
(two studies, n= 233)13,27 are shown in online Figs DS1 and
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187 records identified through
Ovid Medicine, EMBASE
and PsycINFO
(to June 2010)
152 records identified
through PubMed
(to June 2010)
Duplicate records
removed
169 records assessed
for eligibility
14 studies included
in qualitative analysis
19 studies
5 studies included
in meta-regression analysis
155 records excluded:
62 other focus/treatment/diagnosis
38 reviews
36 augmentation therapy
7 open studies
7 dose-finding studies
3 studies of children/adolescents
2 studies with no definition
of response or n510
14 studies excluded from
meta-regression analysis
1 complex study with a multiple
transition among antipsychotics
13 studies without three or more
data
Replacement of search term
‘treatment resistant schizophrenia’
with ‘refractory schizophrenia’
found 5 additional studies
Fig. 1 Literature search.
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DS2. These data are only preliminary in nature, given the small
number of studies and participants.
Discussion
We were interested in whether improvement with antipsychotic
medication might be seen relatively early in treatment-resistant
schizophrenia, similar to the early improvement found in
patients with non-refractory disease.1,2 It would have been
desirable if published antipsychotic trials in this population had
adopted a uniform definition of treatment resistance and treat-
ment response; however, study definitions as well as trial durations
varied considerably, resulting in limited comparability across
studies. Adopting the threshold recently proposed by Leucht et
al (a 25% or more decrease in the BPRS or PANSS)17 would be
expected to result in lower response rates compared with the more
typical 20% cut-off, provided that other absolute criteria were not
used (e.g. a post-treatment CGI-S score of 3 or less, or a BPRS
score of 35 or less).5 This highlights the importance of researchers
reaching a consensus on what constitutes ‘treatment-resistant
schizophrenia’ and ‘treatment response’ thereafter. Moreover,
although an evaluation of a third antipsychotic trial for those
who have already failed to respond to two prospective anti-
psychotic trials appears to be ideal, such studies are few,32–34
and none has specifically reported on the timing issue. This noted,
we evaluated five studies providing at least three LOCF data points
within a 6-week treatment period. Preliminary results indicated
that over this interval the greatest treatment effect (two-thirds
of the improvement) may occur in the first 3 weeks, with more
gradual and attenuated improvement in the following weeks.
Therefore, prolonging an antipsychotic trial dosed appropriately
in a patient with ‘treatment resistance’ in the absence of response
beyond this period might not yield robust benefit, although even
attenuated later improvements can still be of clinical significance.
Determining the time at which the first trial should be abandoned
and a subsequent trial initiated constitutes critical data to guide
therapeutics, a question that only recently has begun to be
addressed.35 This is especially pertinent to patients with treat-
ment-resistant or refractory disorder who are often exposed to
high doses and extended antipsychotic trials in an attempt to elicit
a clinical response.
The results of our study may argue for caution on a ‘wait and
watch’ approach. However, until we know more about possible
differences in trajectory of response in this particular patient
subgroup, it would be premature to argue for discontinuation in
the face of poor response after the first 3–6 weeks, particularly
for clozapine. Moreover, ‘treatment-resistant’ patients clearly
constitute a heterogeneous group, including both patients truly
‘resistant’ to high doses of antipsychotics (e.g. CPZeq 1000mg)
and patients with ‘refractory’ disorder who may be less severely
ill but are unable to tolerate such high doses. In fact, it is possible
that the initial steeper decline in clinical scores is primarily driven
by the latter group.36 In this respect, resistant and intolerant cases
may need to be described separately, although most of the past
studies have failed to do so.
Limitations of the study
Limitations of this investigation include the small number of
studies available for analysis as well as the heterogeneous and
non-standardised nature of the sample, although all patients were
classified as having treatment-resistant/refractory schizophrenia
according to each study. Specifically, a paucity of available data
points precluded quantitative analysis and within-patient
trajectory analysis of response, as well as examination of dose
response for individual antipsychotics. The latter is particularly
pertinent to clozapine with regard to initial titration, final dose
and drug level at steady state.37 More consistent improvement
with clozapine over 6 weeks may be a product of more gradual
titration with this medication at an earlier treatment stage.
Further, some data required extrapolation from figures
accompanying the published reports, although a past work was
obliged to use this strategy as well.1 We restricted the search to
double-blind studies, which is consistent with previous work
involving samples with non-refractory disorder,1,2 but limited
the number of studies analysed. A distinction between completer
and ITT results is important: LOCF data were available for five
studies, whereas only two provided data for completers. The use
of LOCF, a standard method in clinical trials to deal with
participants leaving the study at various time points in the
follow-up period of an intervention study, represents a
compromise by including data from both completer and
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Fig. 2 Standardised individual item mean scores v. week for
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error.
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premature attrition groups. Results should be interpreted with
caution in this regard; although analysing the data for the
completers-only group has the potential of overestimating early
antipsychotic effects, LOCF data may have the opposite effect.
The results described herein should therefore be regarded as
preliminary. Finally, it is important to acknowledge that relevant
outcomes in the longer term are no longer confined to
improvements in symptomatic scores and should be extended to
other relevant areas.38–40 Furthermore, a possibility remains
largely unaddressed that the speed of improvement differs
according to symptoms or illness domains, although data
presentation has not usually been stratified in this respect. Also
pertinent to note is a recent indication that functional outcome
may not be so delayed.41
Future research
To better address the time-line issue it is desirable that future
studies include longitudinal data on response rates as established
by a priori criteria, e.g. 20%, 30%, 50% or 25% (in accordance
with Leucht et al),17 at each available assessment point, the average
score of the primary outcome across time, median/mean time to
response among responders, and time-line by which a certain
percentage of patients are classified as responders, to allow for a
better understanding of a reasonable antipsychotic trial for
challenging patients in clinical practice. The data are better
presented with ITT populations and observed cases at each
assessment. Finally, such data can be interpreted in the context
of the value of early improvement in predicting later response
and the trajectory in response42,43 as well as identifying
persistence on response status on the individual level,44 two
important issues in the management of patients who are
considered to have treatment-resistant disorder.
To conclude, definition of treatment-resistant schizophrenia
and treatment response needs to be carefully delineated, in
combination with more detailed data presentation throughout
the treatment period. Limited evidence from studies longer
than 6 weeks suggests that the greatest treatment effect is within
3–4 weeks. This is in line with what has been reported for
non-refractory patients, but does not necessarily rule out a
delayed onset of antipsychotic action specifically for clozapine.
Future studies need to monitor response earlier in the course of
treatment, whereas longer-term investigations can evaluate the
value of early response in predicting later outcome. It may
well be that there are different trajectories of response, and
distinguishing these will take us a step forward in defining
subgroups, information that would have important clinical
implications.
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